Pediatric anthrax clinical management

Pediatrics

Volumn 133, Issue 5, 2014, Pages

  Bradley, John S ⁱ   Krug, Steven E ⁱ   Bower, William A ⁱ   Cohn, Amanda C ⁱ   Meaney Delman, Dana ⁱ   Pavia, Andrew T ⁱ   Chung, Sarita ⁱ   Fagbuyi, Daniel B ⁱ   Fisher, Margaret ⁱ   Needle, Scott ⁱ   Schonfeld, David J ⁱ   Alexander, John ^a   Garrett, Andrew ^b   Peacock, Georgina ^c   Phillips, Sally ^d   Radden, Erica ^a   Siegel, David ^e   Aird, Laura ⁱ   Diederich, Sean ⁱ   Haro, Tamar ⁱ   Brady, Michael Thomas ⁱ   Byington, Carrie Lynn ⁱ   Davies, H Dele ⁱ   Edwards, Kathryn M ⁱ   Jackson, Mary Anne ⁱ   Maldonado, Yvonne Aida ⁱ   Murray, Dennis ⁱ   Orenstein, Walter A ⁱ   Rathore, Mobeen H ⁱ   Sawyer, Mark H ⁱ   Schutze, Gordon E ⁱ   Willoughby Jr , Rodney E ⁱ   Zaoutis, Theoklis ⁱ   Bernstein, Henry H ⁱ   Kimberlin, David Winston ⁱ   Long, Sarah S ⁱ   Meissner, H Cody ⁱ   Fischer, Marc ^c   Gellin, Bruce ^f   Gorman, Richard L ^g   Lee, Lucia ^a   Pratt, R Douglas ^a   Read, Jennifer S ^a   Robinson, Joan ^h   Safadi, Marco Aurelio Palazzi ⁱ   Seward, Jane ^j   Simon, Geoffrey ^k   Starke, Jeffrey Robert ^l   Tan, Tina Quanbee ^m   Frantz, Jennifer ⁱ   more..

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d US Department of Homeland Security   (United States)

^e National Institute for Child Health and Human Development   (United States)

^f National Vaccine Program Office   (United States)

^g NATIONAL INSTITUTES OF HEALTH   (United States)

^h Canadian Pediatric Society   (Canada)

ⁱ Sociedad Latinoamericana de Infectologia Pediatrica ^*

^j NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^k Committee on Practice and Ambulatory Medicine ^*  (United States)

^l American Thoracic Society   (United States)

^m Pediatric Infectious Diseases Society   (United States)

more..

Author keywords

Anthrax; Anthrax vaccine; Biological weapon; Bioterrorism; Children; Pediatrics; Prophylaxis

Indexed keywords

ANTHRAX VACCINE; ANTIINFECTIVE AGENT; CORTICOSTEROID; BIOLOGICAL WARFARE AGENT; CIPROFLOXACIN; DOXYCYCLINE;

ANTHRAX; ANTIBIOTIC PROPHYLAXIS; ARTICLE; ARTIFICIAL VENTILATION; BACILLUS ANTHRACIS; BACTERIUM CULTURE; BLOOD CULTURE; BREAST FEEDING; CLINICAL FEATURE; COMMUNITY ACQUIRED INFECTION; COMPUTER ASSISTED TOMOGRAPHY; CORTICOSTEROID THERAPY; DIAGNOSTIC TEST; GASTROINTESTINAL INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION PREVENTION; LUNG INFECTION; MENINGITIS; MORTALITY; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; SKIN INFECTION; TREATMENT PLANNING; VACCINATION; ADOLESCENT; BIOLOGICAL WARFARE AGENT; CHILD; DRUG COMBINATION; EDUCATION; HEALTH EDUCATION; IN SERVICE TRAINING; INFANT; NEWBORN; PEDIATRICS; PRESCHOOL CHILD; PUBLIC HEALTH SERVICE; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ANTHRAX; ANTHRAX VACCINES; BACILLUS ANTHRACIS; BIOLOGICAL WARFARE AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHILD; CHILD, PRESCHOOL; CIPROFLOXACIN; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HEALTH EDUCATION; HUMANS; INFANT; INFANT, NEWBORN; INSERVICE TRAINING; PEDIATRICS; UNITED STATES; YOUNG ADULT;

EID: 84899892740     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2014-0563     Document Type: Article

References (115)

1. MacIntyre CR, Seccull A, Lane JM, Plant A. Development of a risk-priority score for category A bioterrorism agents as an aid for public health policy. Mil Med. 2006;171 (7):589-594
2. Inglesby TV, O'Toole T, Henderson DA, et al; Working Group on Civilian Biodefense. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 2002;287(17):2236-2252
3. Franz DR. Preparedness for an anthrax attack. Mol Aspects Med. 2009;30(6):503-510
4. Booth MG, Hood J, Brooks TJ, Hart A; Health Protection Scotland Anthrax Clinical Network. Anthrax infection in drug users. Lancet. 2010;375(9723):1345- 1346
5. Christopher GW, Cieslak TJ, Pavlin JA, Eitzen EM Jr. Biological warfare. A historical perspective. JAMA 1997;278(5):412-417
6. Cieslak TJ, Eitzen EM Jr. Clinical and epidemiologic principles of anthrax. Emerg Infect Dis. 1999;5(4):552-555
7. Swartz MN. Recognition and management of anthrax-an update. N Engl J Med. 2001;345(22):1621-1626
8. Meselson M, Guillemin J, Hugh-Jones M, et al. The Sverdlovsk anthrax outbreak of 1979. Science. 1994;266(5188):1202-1208
9. Jernigan DB, Raghunathan PL, Bell BP, et al; National Anthrax Epidemiologic Investigation Team. Investigation of bioterrorismrelated anthrax, United States, 2001: epidemiologic findings. Emerg Infect Dis. 2002; 8(10):1019-1028
10. Roche KJ, Chang MW, Lazarus H. Images in clinical medicine. Cutaneous anthrax infection. N Engl J Med. 2001;345(22):1611
11. Hendricks KA, Wright ME, Shadomy SV, et al; Workgroup on Anthrax Clinical Guidelines. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2). doi:doi:10.3201/eid2002.130687
12. Centers for Disease Control and Prevention. Children and anthrax: a fact sheet for clinicians. Available at: www.bt.cdc.gov/agent/anthrax/ pediatricfactsheet.asp. Accessed August 21, 2013
13. Steele RW, Thomas MP, Bégué RE.compliance issues related to the selection of antibiotic suspensions for children. Pediatr Infect Dis J. 2001;20(1):1-5
14. American Academy of Pediatrics. Pediatric Preparedness Resource Kit. Elk Grove Village, IL: American Academy of Pediatrics; 2013 [toolkit]
15. American Academy of Pediatrics. Anthrax. In: Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012: 228-232
16. Doganay M, Metan G, Alp E. A review of cutaneous anthrax and its outcome. J Infect Public Health. 2010;3(3):98-105
17. Akbayram S, Dogan M, Akgün C, et al. Clinical findings in children with cutaneous anthrax in eastern Turkey. Pediatr Dermatol. 2010;27(6):600-606
18. Pickering LK, Baker CJ, Kimberlin DW, Long SS, eds. Red Book: 2012 Report of the Committee on Infectious Diseases. 29th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2012
19. Doust JY, Sarkarzadeh A, Kavoossi K. Corticosteroid in treatment of malignant edema of chest wall and neck (anthrax). Dis Chest. 1968;53(6):773-774
20. Glomski IJ. Bacillus anthracis dissemination through hosts. In: Bergman N, ed. Bacillus Anthracis and Anthrax. Hoboken, NJ: Wiley-Blackwell; 2011:227-249
21. Ross JM. The pathogenesis of anthrax following the administration of spores by the respiratory route. J Pathol Bacteriol. 1957;73:485-494
22. Kuehnert MJ, Doyle TJ, Hill HA, et al. Clinical features that discriminate inhalational anthrax from other acute respiratory illnesses. Clin Infect Dis. 2003; 36(3):328-336
23. Klempner MS, Talbot EA, Lee SI, Zaki S, Ferraro MJ. Case records of the Massachusetts General Hospital. Case 25-2010. A 24-year-old woman with abdominal pain and shock. N Engl J Med. 2010;363(8):766-777
24. Albrink WS, Brooks SM, Biron RE, Kopel M. Human inhalation anthrax. A report of three fatal cases. Am J Pathol. 1960;36: 457-471
25. Holty JE, Bravata DM, Liu H, Olshen RA, McDonald KM, Owens DK. Systematic review: a century of inhalational anthrax cases from 1900 to 2005. Ann Intern Med. 2006;144(4):270-280
26. Pile JC, Malone JD, Eitzen EM, Friedlander AM. Anthrax as a potential biological warfare agent. Arch Intern Med. 1998;158 (5):429-434
27. Bravata DM, Holty JE, Wang E, et al. Inhalational, gastrointestinal, and cutaneous anthrax in children: a systematic review of cases: 1900 to 2005. Arch Pediatr Adolesc Med. 2007;161(9):896-905
28. Walsh JJ, Pesik N, Quinn CP, et al. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin Infect Dis. 2007;44(7):968-971
29. Stroud C, Viswanathan K, Powell T, Bass RR, edsInstitute of Medicine, Committee on Prepositioned Medical Countermeasures for the Public. Prepositioning Antibiotics for Anthrax. Washington, DC: National Academies Press; 2012
30. Sirisanthana T, Brown AE. Anthrax of the gastrointestinal tract. Emerg Infect Dis. 2002;8(7):649-651
31. Beatty ME, Ashford DA, Griffin PM, Tauxe RV, Sobel J. Gastrointestinal anthrax: review of the literature. Arch Intern Med. 2003;163(20):2527-2531
32. Ndyabahinduka DG, Chu IH, Abdou AH, Gaifuba JK. An outbreak of human gastrointestinal anthrax. Ann Ist Super Sanita. 1984;20(2-3): 205-208
33. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc Natl Acad Sci U S A. 1993;90(6):2291-2294
34. Centers for Disease Control and Prevention. Anthrax (Bacillus anthracis) 2010 case definition. Available at: wwwn.cdc.gov/nndss/script/casedef.aspx? CondYrID= 609&DatePub=1/1/2010%2012:00:00%20AM. Accessed August 21, 2013
35. Henderson DW, Peacock S, Belton FC. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J Hyg (Lond). 1956;54(1):28-36
36. Manchee RJ, Broster MG, Stagg AJ, Hibbs SE. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish island of Gruinard. Appl Environ Microbiol. 1994;60(11):4167-4171
37. Wright JG, Quinn CP, Shadomy S, Messonnier N; Centers for Disease Control and Prevention (CDC). Use of anthrax vaccine in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep. 2010;59 (RR-6):1-30
38. Friedlander AM, Welkos SL, Pitt ML, et al. Postexposure prophylaxis against experimental inhalation anthrax. J Infect Dis. 1993;167(5):1239-1243
39. US Food and Drug Administration. How to prepare doxycycline for children and adults who cannot swallow pills. Available at: www.fda.gov/downloads/Drugs/ EmergencyPreparedness/Bioterrorismand DrugPreparedness/UCM131001.pdf. Accessed August 21, 2013
40. Lochary ME, Lockhart PB, Williams WT Jr. Doxycycline and staining of permanent teeth. Pediatr Infect Dis J. 1998;17(5):429-431
41. Volovitz B, Shkap R, Amir J, Calderon S, Varsano I, Nussinovitch M. Absence of tooth staining with doxycycline treatment in young children. Clin Pediatr (Phila). 2007;46(2):121-126
42. Meropol SB, Chan KA, Chen Z, et al. Adverse events associated with prolonged antibiotic use. Pharmacoepidemiol Drug Saf. 2008;17(5):523-532
43. Presidential Commission for the Study of Bioethical Issues. Safeguarding children. Pediatric medical countermeasure research. March 2013. Available at: http://bioethics.gov/node/833. Accessed August 21, 2013
44. Kournikakis B, Ho J, Duncan S. Anthrax letters: personal exposure, building contamination, and effectiveness of immediate mitigation measures. J Occup Environ Hyg. 2010;7(2):71-79
45. Yakupogullari Y, Koroglu M. Nosocomial spread of Bacillus anthracis. J Hosp Infect. 2007;66(4):401-402
46. Amidi S, Dutz W, Kohout E, Ronaghy A. Human anthrax in Iran. Report of 300 cases and review of literature. Tropenmed Parasitol. 1974;25(1):96-104
47. Davies JC. A major epidemic of anthrax in Zimbabwe. The experience at the Beatrice Road Infectious Diseases Hospital, Harare. Cent Afr J Med. 1985;31(9):176-180
48. Vietri NJ, Purcell BK, Tobery SA, et al. A short course of antibiotic treatment is effective in preventing death from experimental inhalational anthrax after discontinuing antibiotics. J Infect Dis. 2009; 199(3):336-341
49. Hendricks KA, Wright ME, Shadomy SV, et al. Centers for Disease Control and Prevention expert panel meetings on prevention and treatment of anthrax in adults. Emerg Infect Dis. 2014;20(2). doi: 10.3201/eid2002.130687
50. Durmaz R, Doganay M, Sahin M, et al; Anthrax Study Group. Molecular epidemiology of the Bacillus anthracis isolates collected throughout Turkey from 1983 to 2011. Eur J Clin Microbiol Infect Dis. 2012; 31(10):2783-2790
51. Read TD, Peterson SN, Tourasse N, et al. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature. 2003;423(6935):81-86
52. Turnbull PC, Sirianni NM, LeBron CI, et al. MICs of selected antibiotics for Bacillus anthracis, Bacillus cereus, Bacillus thuringiensis, and Bacillus mycoides from a range of clinical and environmental sources as determined by the Etest. J Clin Microbiol. 2004;42(8): 3626-3634
53. Brook I, Elliott TB, Pryor HI II, et al. In vitro resistance of Bacillus anthracis Sterne to doxycycline, macrolides and quinolones. Int J Antimicrob Agents. 2001;18(6):559-562
54. Bradley JS, Jackson MA; Committee on Infectious Diseases; American Academy of Pediatrics. The use of systemic and topical fluoroquinolones. Pediatrics. 2011;128 (4). Available at: www.pediatrics.org/cgi/content/full/128/ 4/e1034
55. Cale DF, McCarthy MW. Treatment of Rocky Mountain spotted fever in children. Ann Pharmacother. 1997;31(4):492-494
56. Stevens DL. Streptococcal toxic shock syndrome associated with necrotizing fasciitis. Annu Rev Med. 2000;51:271-288
57. Bisno AL, Stevens DL. Streptococcal infections of skin and soft tissues. N Engl J Med. 1996;334(4):240-245
58. Zimbelman J, Palmer A, Todd J. Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive Streptococcus pyogenes infection. Pediatr Infect Dis J. 1999;18(12):1096-1100
59. Regan JC. The local and general serum treatment of cutaneous anthrax. JAMA 1921;77:1944-1948
60. Pijper A. The treatment of human anthrax. Lancet. 1926;210:88-89
61. Binkley CE, Cinti S, Simeone DM, Colletti LM. Bacillus anthracis as an agent of bioterrorism: a review emphasizing surgical treatment. Ann Surg. 2002;236(1): 9-16
62. Knox D, Murray G, Millar M, et al. Subcutaneous anthrax in three intravenous drug users: a new clinical diagnosis. J Bone Joint Surg Br. 2011;93(3):414-417
63. Wood BJ, DeFranco B, Ripple M, et al. Inhalational anthrax: radiologic and pathologic findings in two cases. AJR Am J Roentgenol. 2003;181(4):1071-1078
64. Thwaites GE, Bhavnani SM, Chau TT, et al. Randomized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis. Antimicrob Agents Chemother. 2011;55(7):3244-3253
65. Ruslami R, Ganiem AR, Dian S, et al. Intensified regimen containing rifampicin and moxifloxacin for tuberculous meningitis: an open-label, randomised controlled phase 2 trial. Lancet Infect Dis. 2013;13(1): 27-35
66. Norrby SR. Neurotoxicity of carbapenem antibiotics: consequences for their use in bacterial meningitis. J Antimicrob Chemother. 2000;45(1):5-7
67. Wong VK, Wright HT, Jr, Ross LA, Mason WH, Inderlied CB, Kim KS. Imipenem/cilastatin treatment of bacterial meningitis in children. Pediatr Infect Dis J. 1991;10 (2):122-125
68. Stucki A, Cottagnoud M, Acosta F, Egerman U, Laeuffer JM, Cottagnoud P. Efficacy of doripenem against Escherichia coli and Klebsiella pneumoniae in experimental meningitis. J Antimicrob Chemother. 2012; 67(3):661-665
69. Sejvar JJ, Tenover FC, Stephens DS. Management of anthrax meningitis. Lancet Infect Dis. 2005;5(5):287-295
70. Yogev R, Damle B, Levy G, Nachman S. Pharmacokinetics and distribution of linezolid in cerebrospinal fluid in children and adolescents. Pediatr Infect Dis J. 2010;29(9):827-830
71. Villani P, Regazzi MB, Marubbi F, et al. Cerebrospinal fluid linezolid concentrations in postneurosurgical central nervous system infections. Antimicrob Agents Chemother. 2002;46(3):936-937
72. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin-resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis. 2001;33(5):375-379
73. París MM, Shelton S, Trujillo M, Hickey SM, McCracken GH Jr. Clindamycin therapy of experimental meningitis caused by penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Antimicrob Agents Chemother. 1996;40(1):122-126
74. Lee E, Burger S, Shah J, et al. Linezolidassociated toxic optic neuropathy: a report of 2 cases. Clin Infect Dis. 2003;37 (10):1389-1391
75. Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect Dis. 2004;4(8):528-531
76. Nambiar S, Rellosa N, Wassel RT, Borders-Hemphill V, Bradley JS. Linezolid-associated peripheral and optic neuropathy in children. Pediatrics. 2011;127(6). Available at: www.pediatrics.org/cgi/content/full/127/6/e1528
77. Gerson SL, Kaplan SL, Bruss JB, et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother. 2002;46(8):2723-2726
78. Clarke PS. Chloramphenicol in treatment of cutaneous anthrax. BMJ. 1952;1(4749): 86-87
79. Lebel MH, Freij BJ, Syrogiannopoulos GA, et al. Dexamethasone therapy for bacterial meningitis. Results of two doubleblind, placebo-controlled trials. N Engl J Med. 1988;319(15):964-971
80. Moayeri M, Leppla SH. The roles of anthrax toxin in pathogenesis. Curr Opin Microbiol. 2004;7(1):19-24
81. Chung AM, Reed MD, Blumer JL. Antibiotics and breastfeeding: a critical review of the literature. Paediatr Drugs. 2002;4(12):817-837
82. Stern EJ, Uhde KB, Shadomy SV, Messonnier N. Conference report on public health and clinical guidelines for anthrax. Emerg Infect Dis. 2008;14(4). doi:doi:10.3201/eid1404. 070969
83. Meaney-Delman D, Zotti ME, Creanga AA, et al; Workgroup on Anthrax in Pregnant and Postpartum Women. Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women. Emerg Infect Dis. 2014;20(2). doi: doi:10.3201/eid2002.130611
84. American Academy of Pediatrics. Antimicrobial therapy for newborns. In: Bradley JS, Nelson JD, eds. 2012-2013 Nelson's Pediatric Antimicrobial Therapy. 19th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2013:17-35
85. Belet N, Haciömeroglu P, Küçüködük S. Ciprofloxacin treatment in newborns with multi-drug-resistant nosocomial Pseudomonas infections. Biol Neonate. 2004;85 (4):263-268
86. Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin use in neonates: a systematic review of the literature. Pediatr Infect Dis J. 2011;30(2):e29-e37
87. Aggarwal P, Dutta S, Garg SK, Narang A. Multiple dose pharmacokinetics of ciprofloxacin in preterm babies. Indian Pediatr. 2004;41(10):1001-1007
88. Anderson VR, Perry CM. Levofloxacin: a review of its use as a high-dose, shortcourse treatment for bacterial infection. Drugs. 2008;68(4):535-565
89. Hata A, Honda Y, Asada K, Sasaki Y, Kenri T, Hata D. Mycoplasma hominis meningitis in a neonate: case report and review. J Infect. 2008;57(4):338-343
90. Watt KM, Massaro MM, Smith B, Cohen-Wolkowiez M, Benjamin DK, Jr, Laughon MM. Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis. Pediatr Infect Dis J. 2012;31(2):197-199
91. Bradley JS, Sauberan JB, Ambrose PG, Bhavnani SM, Rasmussen MR, Capparelli EV. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J. 2008;27(9):794-799
92. Smith PB, Cohen-Wolkowiez M, Castro LM, et al; Meropenem Study Team. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intraabdominal infections. Pediatr Infect Dis J. 2011;30(10):844-849
93. van den Anker JN, Pokorna P, Kinzig-Schippers M, et al. Meropenem pharmacokinetics in the newborn. Antimicrob Agents Chemother. 2009;53(9):3871-3879
94. Böswald M, Döbig C, Kändler C, et al. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. Infection. 1999;27(4-5):299-304
95. Giannoni E, Moreillon P, Cotting J, et al. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob Agents Chemother. 2006;50(7):2563-2568
96. Reed MD, Kliegman RM, Yamashita TS, Myers CM, Blumer JL. Clinical pharmacology of imipenemand cilastatin in premature infants during the first week of life. Antimicrob Agents Chemother. 1990;34(6):1172-1177
97. Metsvaht T, Oselin K, Ilmoja ML, Anier K, Lutsar I. Pharmacokinetics of penicillin g in very-low-birth-weight neonates. Antimicrob Agents Chemother. 2007;51(6):1995-2000
98. Muller AE, DeJongh J, Bult Y, et al. Pharmacokinetics of penicillin G in infants with a gestational age of less than 32 weeks. Antimicrob Agents Chemother. 2007;51 (10):3720-3725
99. Dotis J, Iosifidis E, Ioannidou M, Roilides E. Use of linezolid in pediatrics: a critical review. Int J Infect Dis. 2010;14(8):e638-e648
100. Hoehn R, Groll AH, Schaefer V, Bauer K, Schloesser RL. Linezolid treatment of glycopeptide-resistant Enterococcus faecium in very low birth weight premature neonates. Int J Antimicrob Agents. 2006;27 (3):256-258
101. Kocher S, Müller W, Resch B. Linezolid treatment of nosocomial bacterial infection with multiresistant gram-positive pathogens in preterm infants: a systematic review. Int J Antimicrob Agents. 2010;36(2):106-110
102. Kearns GL, Jungbluth GL, Abdel-Rahman SM, et al; Pediatric Pharmacology Research Unit Network. Impact of ontogeny on linezolid disposition in neonates and infants. Clin Pharmacol Ther. 2003;74(5):413-422
103. Shama A, Patole SK, Whitehall JS. Intravenous rifampicin in neonates with persistent staphylococcal bacteraemia. Acta Paediatr. 2002;91(6):670-673
104. Tan TQ, Mason EO, Jr, Ou CN, Kaplan SL. Use of intravenous rifampin in neonates with persistent staphylococcal bacteremia. Antimicrob Agents Chemother. 1993; 37(11):2401-2406
105. van der Lugt NM, Steggerda SJ, Walther FJ. Use of rifampin in persistent coagulase negative staphylococcal bacteremia in neonates. BMC Pediatr. 2010;10:84
106. Shetty AK. Tetracyclines in pediatrics revisited. Clin Pediatr (Phila). 2002;41(4): 203-209
107. Lubani MM, Dudin KI, Sharda DC, et al. A multicenter therapeutic study of 1100 children with brucellosis. Pediatr Infect Dis J. 1989;8(2):75-78
108. Alexander JJ, Colangelo PM, Cooper CK, Roberts R, Rodriguez WJ, Murphy MD. Amoxicillin for postexposure inhalational anthrax in pediatrics: rationale for dosing recommendations. Pediatr Infect Dis J. 2008;27(11):955-957
109. Charles BG, Preechagoon Y, Lee TC, Steer PA, Flenady VJ, Debuse N. Population pharmacokinetics of intravenous amoxicillin in very low birth weight infants. J Pharm Sci. 1997;86(11):1288-1292
110. Huisman-de Boer JJ, van den Anker JN, Vogel M, Goessens WH, Schoemaker RC, de Groot R. Amoxicillin pharmacokinetics in preterm infants with gestational ages of less than 32 weeks. Antimicrob Agents Chemother. 1995;39(2):431-434
111. Pullen J, Stolk LM, Nieman FH, Degraeuwe PL, van Tiel FH, Zimmermann LJ. Population pharmacokinetics and dosing of amoxicillin in (pre)term neonates. Ther Drug Monit. 2006;28(2):226-231
112. Ahmed AS, Khan NZ, Saha SK, et al. Ciprofloxacin treatment in preterm neonates in Bangladesh: lack of effects on growth and development. Pediatr Infect Dis J. 2006;25(12):1137-1141
113. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones: focus on respiratory infections. Drugs. 2002;62(1):13-59
114. Grossman ER, Walchek A, Freedman H. Tetracyclines and permanent teeth: the relation between dose and tooth color. Pediatrics. 1971;47(3):567-570
115. Martin SW, Tierney BC, Aranas A, et al. An overview of adverse events reported by participants in CDC's anthrax vaccine and antimicrobial availability program. Pharmacoepidemiol Drug Saf. 2005;14(6):393-401